The Van Poznak/Estilo article reviewed

ONCOLOGY

Volumn 20, Issue 9, 2006, Pages 1065-1066

  Berenson, James R ^a   Yeh, Howard S ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER PATIENT; CLINICAL PRACTICE; DISEASE SEVERITY; HUMAN; JAW OSTEONECROSIS; MULTIPLE MYELOMA; NOTE; PRACTICE GUIDELINE; PREVALENCE; RISK ASSESSMENT;

EID: 34250644311     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493, 1996.
2. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone lesions. N Engl J Med 335:1785-1791, 1996.
3. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999.
4. Rosen LS, Gordon D, Kaminski M, et al: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744, 2003.
5. Rosen LS, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003.
6. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002.
7. Berenson JR, Hillner BE, Kyle RA, et al: American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20(17):3719-3736, 2002.
8. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042-4057, 2003.
9. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al: Osteonecrosis of me jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534, 2004.
10. Durie BGM, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99, 2005.
11. Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23:8580-8587, 2005.
12. Van Poznak CH, Estilo CL, Sauter NP, et al: Osteonecrosis of the jaw in patients with metastatic breast cancer (abstract 3057). Breast Cancer Res Treat 88(suppl 1):S131, 2004.
13. Hoff AO, Toth B, Altundag K, et al: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (abstract 1218). J Bone Miner Res 20(suppl 1):555, 2005.
14. American Association of Oral and Maxillofacial Surgeons: http://www.aaoms.org.